Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amrubicin in Advanced/Metastatic Refractory Urothelial Carcinoma
NCT01331824Phase 2Terminated
- Start
- Feb 2011
- Primary completion
- Jul 2014
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of amrubicin in urothelial carcinoma (UC). Started Feb 2011; status: terminated.
02
Drugs
amrubicin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT01331824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01331824.